The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Katherine A Guthrie
No Relationships to Disclose
 
Mohamed E. Salem
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Exelixis; Merck; Novartis; Pfizer; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - BMS; Daiichi Sankyo/Astra Zeneca; Merck; Pfizer; Taiho Pharmaceutical
 
Katrina Sophia Pedersen
Consulting or Advisory Role - Array BioPharma; Bayer; Novartis; Pfizer
Speakers' Bureau - Clinical Care Options; WebMD
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Ipsen (Inst); Merck (Inst); Natera (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Array BioPharma; BeiGene; Nouscom
Other Relationship - UpToDate
(OPTIONAL) Uncompensated Relationships - NCCN
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - Boston Scientific; BTG; Exelixis; Incyte; QED Therapeutics
Speakers' Bureau - Boston Scientific; Exelixis; Genentech/Roche
Research Funding - Bristol-Myers Squibb (Inst)
 
Sarah Colby
No Relationships to Disclose
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Incyte; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); Verastem (Inst)
 
Sepideh Gholami
Consulting or Advisory Role - QED Therapeutics
Speakers' Bureau - Helsinn Therapeutics
 
Philip Jordan Gold
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Axiom Healthcare Strategies; Bayer; BioNTech; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; Ipsen; Merck; Novartis; Noxxon Pharma; Noxxon Pharma; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); FibroGen (Inst); Halozyme (Inst); Lonza (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Bayer; Genentech; Merck
Speakers' Bureau - Natera
 
Philip Agop Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals